文献速递妇科肿瘤

维利帕尼联合一线化疗及维持治疗卵巢癌:最终总生存与疾病相关症状结果

Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
PubMed 文献 · Eur J Cancer · 2025-06-17

VELIA试验纳入1140例III/IV期高级别浆液性卵巢癌患者,随机分三组。最终分析显示,维利帕尼全程组中位总生存59.2个月,联合组58.0个月,安慰剂组57.8个月,组间无显著差异,BRCA缺陷及同源重组缺陷队列亦然。未发现新的安全性信号,疾病相关症状无显著额外负担。

要点

  • 维利帕尼全程组中位总生存59.2个月,联合组58.0个月,安慰剂组57.8个月,组间无显著差异。
  • 在BRCA缺陷和同源重组缺陷队列中,总生存亦无显著差异。
  • 未发现新的安全性信号,疾病相关症状无显著额外负担。

核心结论

  • 尽管无进展生存期观察到获益,但本研究未检测到维利帕尼联合铂类化疗并维持治疗在总生存或疾病相关症状方面的获益。

研究设计与样本

  • 随机、安慰剂对照、双盲、多中心、3期研究,纳入1140例初诊III/IV期高级别浆液性卵巢癌成人女性,按1:1:1随机分为维利帕尼全程组、维利帕尼联合组和安慰剂全程组。

主要发现

  • 在意向治疗人群(N=1140)中,维利帕尼全程组中位总生存59.2个月(95%CI 52.1, 68.2),维利帕尼联合组58.0个月(95%CI 50.6, 64.1),安慰剂全程组57.8个月(95%CI 52.3, 63.8)。
  • 总生存结局在各组间总体无显著差异,在BRCA缺陷和同源重组缺陷队列中亦无显著差异。
  • 较长的随访期间未发现新的安全性信号,疾病相关症状分析表明,在化疗中加入维利帕尼或用于维持治疗时,总体未出现显著的额外症状相关负担。

临床怎么用

  • 作者结论为:本研究未检测到维利帕尼联合铂类化疗并维持治疗在总生存或疾病相关症状方面的获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the VELIA trial, the addition of veliparib to standard first-line platinum-based chemotherapy and continued as maintenance resulted in significantly longer median progression-free survival (PFS) compared with carboplatin plus paclitaxel induction therapy alone (23.5 vs 17.3 months; p < 0.001) in patients with ovarian cancer. We now report final overall survival (OS) and updated safety and disease-related symptoms (DRS) from patient-reported outcomes of the trial. METHODS: This randomized, placebo-controlled, double-blind, multicenter, phase 3 study enrolled adult women with an initial diagnosis of stage III/IV high-grade serous ovarian cancer undergoing primary or interval cytoreductive surgery. Patients were randomized 1:1:1 to chemotherapy plus veliparib followed by veliparib maintenance (veliparib-throughout), chemotherapy plus veliparib followed by placebo maintenance (veliparib-combination-only), or chemotherapy plus placebo followed by placebo maintenance (placebo-throughout). PFS was the primary endpoint; OS and DRS were secondary endpoints. RESULTS: In the intention-to-treat population (N = 1140), median OS was 59.2 months (95 % confidence interval: 52.1, 68.2) for the veliparib-throughout group, 58.0 (50.6, 64.1) months for veliparib-combination-only, and 57.8 (52.3, 63.8) months for placebo-throughout. OS outcomes were not significantly different between arms overall or in the BRCA-deficient and homologous recombination-deficient cohorts. No new safety signals were identified during the longer follow-up period and DRS analyses indicated there was no significant additional symptom-related burden overall when veliparib was added to chemotherapy or used for maintenance. CONCLUSION: No OS or DRS benefit of addition of veliparib to platinum-based chemotherapy and continued as maintenance therapy was detected in this study, despite an observed benefit over chemotherapy alone in PFS.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Coleman RL, Fleming GF, Brady MF, et al. Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results. Eur J Cancer. 2025. PMID: 40561681. doi:10.1016/j.ejca.2025.115587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。